Microglial dysfunction as a key pathological change in adrenomyeloneuropathy

Citation
Gong, Yi, Nikhil Sasidharan, Fiza Laheji, Matthew Frosch, Patricia Musolino, Rudy Tanzi, Doo Yeon Kim, Alessandra Biffi, Joseph El Khoury, and Florian Eichler. 2017. “Microglial dysfunction as a key pathological change in adrenomyeloneuropathy.” Annals of Neurology 82 (5): 813-827. doi:10.1002/ana.25085. http://dx.doi.org/10.1002/ana.25085.

Published Version
doi:10.1002/ana.25085

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651740

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Microglial Dysfunction as a Key Pathological Change in Adrenomyeloneuropathy

Yi Gong, PhD,1 Nikhil Sasidharan, PhD,1 Fiza Laheji, MD,1 Matthew Frosch, MD, PhD,1 Patricia Musolino, MD, PhD,1 Rudy Tanzi, PhD,1 Doo Yeon Kim, PhD,1 Alessandra Biffi, MD,2 Joseph El Khoury, MD,1 and Florian Eichler, MD1

Objective: Mutations in ABCD1 cause the neurodegenerative disease, adrenoleukodystrophy, which manifests as the spinal cord axonopathy adrenomyeloneuropathy (AMN) in nearly all males surviving into adulthood. Microglial dysfunction has long been implicated in pathogenesis of brain disease, but its role in the spinal cord is unclear.

Methods: We assessed spinal cord microglia in humans and mice with AMN and investigated the role of ABCD1 in microglial activity toward neuronal phagocytosis in cell culture. Because mutations in ABCD1 lead to incorporation of very-long-chain fatty acids into phospholipids, we separately examined the effects of lysophosphatidylcholine (LPC) upon microglia.

Results: Within the spinal cord of humans and mice with AMN, upregulation of several phagocytosis-related markers, such as MFGE8 and TREM2, precedes complement activation and synapse loss. Unexpectedly, this occurs in the absence of overt inflammation. LPC C26:0 added to ABCD1-deficient microglia in culture further enhances MFGE8 expression, aggravates phagocytosis, and leads to neuronal injury. Furthermore, exposure to a MFGE8-blocking antibody reduces phagocytic activity.

Interpretation: Spinal cord microglia lacking ABCD1 are primed for phagocytosis, affecting neurons within an altered metabolic milieu. Blocking phagocytosis or specific phagocytic receptors may alleviate synapse loss and axonal degeneration.

© 2017 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association

Received May 25, 2017, and in revised form Oct 20, 2017. Accepted for publication Oct 20, 2017.

Address correspondence to Dr Florian S. Eichler. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, ACC 708, Boston, MA 02114. E-mail: feichler@partners.org

From the 1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and 2Boston Children’s Hospital, Dana Farber Cancer Institute, Boston, MA.
These discrepancies may be resolved by a closer examination of the cellular constituents of pathology in relation to ABCD1 gene expression. ABCD1 is not uniformly expressed across different cell types. How can axons be affected when ABCD1 is only expressed in neurons at very low levels? Microglia have recently been implicated as potential cellular mediators of synapse loss. Specific transcriptional and functional alterations of microglia vary in each neurological disease depending on pathology and type of molecular stimuli encountered. Given that ABCD1 is highly expressed in microglia, it is possible that microglial dysfunction in its close interaction with other cell types actively participates in the neurodegenerative process.

Importantly, ABCD1 deficiency in mice also leads to axonal degeneration, resembling findings in AMN patients. In AMN mice, previous studies have noted that microglial activation coincides with noninflammatory axonal degeneration; similar observations have been made in human AMN spinal cord. Despite these findings, no detailed studies on the molecular and functional change of microglia in the absence of ABCD1 have been conducted, and the impact of microglia upon long-tract degeneration remains unclear. The aim of the present study was to systematically define microglia in human and mouse spinal cord and further explore dysfunction of ABCD1-deficient microglia both in vivo and in vitro.

Materials and Methods

Animals
Wild-type (WT) C57BL/6 and congenic C57BL/6 Abcd1−/− mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Abcd1−/− mice were back-crossed onto a pure C57/B6 background over six generations. They were then bred from homozygous founders and occasionally genotyped. Mice were fed a standard diet and maintained under a 12-hour light-dark cycle. Only male mice were used for the experiments.

Mouse Tissue Preparation
Mice were anesthetized by isoflurane and sacrificed by transcardial perfusion of phosphate-buffered saline (PBS). Brain and spinal cord were immediately dissected and snap-frozen. Parts of tissues were fixed by 4% paraformaldehyde (PFA) and equilibrated in 30% sucrose before slicing.

Primary Neonatal Microglial Cultures and N9 Microglia Culture
Microglia cultures were prepared as previously described. Briefly, mixed glial cultures (~95% astrocytes, ~5% microglia) were prepared from the brain tissue of 1- to 3-day-old mice. The tissue was trypsinized with 0.05% trypsin, and cells were resuspended in glia complete medium Dulbecco’s modified Eagle’s medium (DMEM; Lonza Biologics Inc, Portsmouth, NH) supplemented with 10% fetal bovine serum (FBS), 100IU/ml of penicillin, 100 µg/ml of streptomycin, and 2mM of l-glutamine. After 10 to 14 days in culture, microglia were isolated from the mixed glial cultures by the shake-off procedure. Specifically, loosely attached microglia were obtained from an incubator shaker at 250rpm for 2 hours at 37°C, then the cell-containing medium was centrifuged at 1,100rpm for 3 minutes to collect microglia for subsequent culture. N9 microglia cells were cultured in RPMI 1640 medium supplemented with 10% FBS.

Differentiated Neuronal Culture
Immortalized hNPC cell line ReNcell VM (ReN) was used to differentiate into neurons per published protocol. Simply, ReN cells were grown in proliferation medium (DMEM/F12; Gibco/Life Technologies, Grand Island, NY) with 2 µg/ml of heparin (stock; STEMCELL Technologies, Cambridge, MA), 2% B27 (Life Technologies, Carlsbad, CA), 20ng/ml of epidermal growth factor (EGF), 20ng/ml of basic fibroblast growth factor, and 1% of 100 X penicillin/streptomycin (Gibco/Life Technologies) until confluency. For differentiation, 3 X 10⁴ cells were seeded on Matrigel-coated (1:100 dilution in DMEM/F12) eight-well chamber slides and grown in differentiation medium (DMEM/F12; Gibco/Life Technologies) with 2 µg/ml of heparin (stock; STEMCELL Technologies), 2% B27 (Life Technologies), and 1% of 100 X penicillin/streptomycin (Gibco/Life Technologies) for 2 to 3 weeks before coculture with microglia.

Cocultures and VLCFA Supplementation
For the coculture of microglia and neurons, isolated microglia were seeded on top of differentiated neurons and cocultured in differentiated medium for 4 days with or without supplementation of VLCFA. For VLCFA supplementation, hexacosanoic acid (free fatty acid [FFA] C26:0) and lysophosphatidylcholine (LPC) C16:0 and C26:0 (Avanti Polar Lipids, Inc., Alabaster, AL) were solubilized in 50mg/ml of methyl-β-cyclodextrin to make 3mM of stock solution and then supplemented into culture medium to reach designated concentration with methyl-β-cyclodextrin as vehicle control. After coculture for 4 days, cells were fixed in PFA and immunostained with beta-III-tubulin (TuJ1), which is a β-tubulin family structural protein expressed in neurons, and ionizing calcium-binding adaptor molecule 1 (IBA1) that marks microglia. MFGE8 blocking antibody (R&D Systems, Minneapolis, MN) or control immunoglobulin G (IgG; R&D Systems) were added to the coculture to assess the function of MFGE8. TuJ1 immunofluorescence and degenerated axons were quantified in each group.

Microglial Phagocytosis Assay
Microglia were seeded in an eight-well chamber (7 X 10⁴/well in complete medium) and cultured for 24 hours. SH-SY5Y cells were treated with 100 µM of H₂O₂ for 12 hours to induce phosphatidylserine (PS) exposure on the cell surface. Floating SH-SY5Y cells were then collected by centrifuge at 1,000rpm for 3 minutes, resuspended in serum-free medium, and stained.
with 3 μM of fluorescent probe CMTPX (red; 1:1,000 dilution; Life Science Technologies) for 30 minutes. A portion of the floating cells was subjected to Annexin V/FITC (fluorescein isothiocyanate) staining to confirm the exposure of PS. The remainder was washed twice and seeded (same amount as microglia) on top of the microglial layer. After a 4-hour coculture, cells were washed with PBS and fixed with 4% PFA for 15 minutes at room temperature. Microglia were then stained with IBA1 antibody (Wako Chemicals USA, Inc., Richmond, VA) overnight followed by Alexa Fluor-488–conjugated secondary antibody. For quantification, five random images were taken from each chamber well using a confocal microscope (Carl Zeiss, Jena, Germany). The total number of phagocytosed particles as well as cell-sized particles was counted and divided by microglia cell number. To validate the function of MFGE8, microglia were pretreated with recombinant MFGE8 (50ng/ml; R&D Systems) or MFGE8 blocking antibody for 12 hours and then the phagocytosis assay was performed as listed above.

Western Blotting

Tissue and cell lysates were prepared using radioimmunoprecipitation assay buffer (Sigma-Aldrich, St. Louis, MO) with 1% Halt Protease and Phosphatase Inhibitor Cocktail (Roche, Indianapolis, IN). Protein samples were separated on NuPAGE 4% to 12% Bis-tris gels (Life Science Technologies) and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). Membranes were blocked with 5% nonfat milk in PBS containing 0.05% Tween 20 and probed with antibodies against inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (Cox2; Santa Cruz Biotechnology, Santa Cruz, CA), ABCD1, C1q, postsynaptic density protein 95 (PSD95), and CD11b (Abcam, Cambridge, MA), synaptophysin (Cell Signaling Technology, Danvers, MA), MFGE8 (MBL International Corporation, Woburn, MA), IBA1 (Wako Chemicals USA, Inc.), β-actin or glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology) were used as protein loading control. Membranes were developed with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA) after incubation with horseradish peroxidase–conjugated secondary antibodies. Antibodies that differed in human specimen included anti-human MFGE8 (Sigma-Aldrich) and anti-human ABCD1 (Origene, Rockville, MD).

Quantitative Real-Time Reverse Transcription PCR

Total RNA from cells or tissues were isolated using the Qiagen RNeasy Mini Kit (Qiagen). First-strand complementary DNA synthesis used 100ng of random primer (Life Technologies), 1.0μg of total RNA, 10 mM of deoxynucleotide, and 200 units of reverse transcriptase (Life Technologies) per 20 μl reactions. PCRs were performed in duplicates in a 25 μl final volume by using SYBR Green master mix from Applied Biosystems (Life Technologies). The data were analyzed by calculating the delta threshold cycle value between the tested gene and an internal control.

Immunofluorescence Staining and Confocal Microscopy Imaging

Spinal cord sections (14-μm) were cut at –25°C using cryostat (Leica Microsystems, Wetzlar, Germany) and permeabilized in blocking buffer containing 0.3% Triton X and 2% goat serum for 1 hour. Sections were then stained with IBA1 (Wako Chemicals USA, Inc.), CD68 (Bio-Rad for mouse and Abcam for human; Bio-Rad Laboratories, Hercules, CA), synaptophysin (Sigma-Aldrich), C1q and von Willebrand factor (VWF) (Abcam), Fibrinogen (Millipore), Neurofilament (NF) (BioLegend, Dedham, MA), and neuronal nuclei (NeuN) (Abcam) antibodies, respectively.

Enzyme-Linked Immunosorbent Assay

MFGE8, tumor necrosis factor alpha (TNFα) and interleukin (IL) 1β level in culture medium and spinal cord homogenate were measured using an MFGE8, IL1β, and TNFα enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems) according to the manufacturer’s instructions.

Human Spinal Cord Specimen

Human tissue study was performed on postmortem spinal cord tissue from 13 adult ALD cases (8 AMN cases, 5 cerebral ALD [c-ALD] only, and 9 control cases obtained from NIH Neuro-BioBank). Use of this material was approved by the Institutional Review Board of Massachusetts General Hospital (Boston, MA).

Statistical Analysis

Results were expressed as means ± standard error of the mean (SEM) and analyzed for statistical significance by analysis of variance followed by Fisher’s protected least-significant difference based on two-side comparisons among experimental groups using an SPSS program (SPSS, Inc., Chicago, IL). A value of p < 0.05 was considered statistically significant.

Results

In the Spinal Cord of Aging Abcd1−/− Mice, Microglial Activation Precedes Synapse Loss

Abcd1−/− mice develop an AMN-like phenotype at an advanced age. Synapse loss has long been considered an integral aspect of neurodegeneration. Hence, we set out to examine the time course of axon degeneration and microglial activation in spinal cord. We found that as early as 8 months before synapse loss, spinal cord microglia of Abcd1−/− mice display an enlarged soma and upregulated CD68 expression (Fig 1). This activation of Abcd1−/− microglia coincided with them enveloping synapses and axons (Fig 2FH), active synaptic pruning, and reduced presynaptic synaptophysin (SYP) and postsynaptic PSD95 (Fig 2). These data suggest that microglia are actively contributing to axonal degeneration. Importantly, vessel walls were intact and no significant mononuclear activation was observed around the vessel, suggesting that innate immune activation in AMN mice is largely attributed to resident microglia alone (Fig 2).
To determine whether inflammation is involved in AMN disease progression, we measured several proinflammatory biomarkers that are usually upregulated during inflammation. At both 2 and 15 months, no significant changes in expression of proinflammatory genes and proteins were detected in Abcd1<sup>−/−</sup> mouse spinal cord (Fig 3A–C). Next, we set out to determine the expression of several key receptors and signaling molecules for phagocytosis.

To our surprise, there was a significant increase of Trem2 gene expression (as well as minor, but not significant, increases in Clqa, MFGE8, Gas6, and Bai1) in spinal cord of young 2-month-old Abcd1<sup>−/−</sup> mice.
FIGURE 2: The presence of synapse loss, a marker of axon degeneration at different ages in Abcd1−/− mice spinal cord. (A) Representative western blot showed presynaptic synaptophysin (SYP) and postsynaptic PSD95 expression in Abcd1−/− spinal cord across different ages and (B) synaptophysin as well as (C) PSD95 protein quantification using ImageJ (NIH, Bethesda, MD) with β-actin as loading control (n = 4 at 2 months, n = 5 at 8 months, and n = 12 at 15 months). (D) Synaptophysin (SYP) and (E) PSD95 (DLG4) gene expression in Abcd1−/− spinal cord at different ages (n = 4 at 2 months and n = 12 at 15 months). (F) Co-staining of IBA1 (green) and NeuN (red) as well as neurofilament (NF; red) shows activated microglia surrounding neurons and neurites in 15-month-old Abcd1−/− mouse spinal cord. (G) Immunofluorescence quantification of synaptophysin pixels in 15-month-old spinal cord using ImageJ (n = 7). (H) Three-dimensional confocal images show microglia (CD68 red) engulfing synapses (synaptophysin green) in 15-month-old mouse spinal cord (indicated by white arrow). In wild-type spinal cord, more punctate synaptophysin staining is present compared to the Abcd1−/− spinal cord where synapse loss occurs. Data are expressed as mean ± SEM; *p < 0.05; **p < 0.001. DLG4 = disks large homolog 4; IBA1 = ionizing calcium-binding adaptor molecule 1; PSD95 = postsynaptic density protein 95; NeuN = neuronal nuclei; SEM = standard error of the mean; WT = wild type.
By 15 months of age, a remarkable upregulation of Trem2, C1qa, and MFGE8 mRNA was evident (Fig 3G; \( p < 0.05 \)), coinciding with prominent C1q and MFGE8 protein upregulation (Fig 3H,I). Costaining of synaptophysin and C1q at different ages showed frequent colocalization suggesting a role of C1q in synaptic pruning and axonal degeneration (Fig 3J). Interestingly, the transforming growth factor beta (TGF\( \beta \)) family of genes, especially TGF\( \beta \)2, that is known to regulate C1q and MFGE8, showed significant upregulation at both 2 and 15 months (Fig 3K,L).

**In Vitro, ABCD1-Deficient Microglia Lack an Inflammatory Profile but Increase Phagocytosis of PS Exposing Neurons**

To learn whether microglial changes observed in vivo were primary or secondary to axon degeneration, we isolated microglia from postnatal mice and assessed molecular changes in unstimulated conditions as well as after lipopolysaccharide (LPS) challenge. In a quiescent state, the expression of several major proinflammatory biomarkers, including IL1b, TNF, NOS2, and Cox2, were very low in Abcd1\(^{−/−}\) mice. However, an LPS challenge
(1 µg/ml) led to a significant upregulation in mRNA of IL1β, NOS2, and Cox2 compared to WT, suggesting that microglia in Abcd1–/– mice are primed to respond to stimuli (Fig 4A). Higher IBA1 and CD11b expression was detected in both quiescent and LPS-challenged states (Fig 4B).

After observing an unexpected increase of phagocytosis-related biomarkers at tissue level, we wondered whether gene expression of these markers would be altered in vitro as well. Indeed, we found significantly higher levels of Bai1, Gas6, MFGE8, and Trem2 in Abcd1−/− microglia, with MFGE8 displaying a 3-fold increase (Fig 4C; *p < 0.05). An ELISA assay detected 2-fold higher MFGE8 protein secretion into media by Abcd1–/– microglia (Fig 4D; *p < 0.05). During classical microglial activation, LPS can significantly reduce MFGE8 expression (Fig 4C,D) while increasing phagocytic activity (Fig 4F). This is consistent with other past reports performed under WT conditions.18–20

As a bridging protein, MFGE8 tightly binds to exposed PS on surface membranes of stressed neurons and opsonizes them for phagocytosis. Indeed, in coculture we found that Abcd1−/− microglia increased phagocytosis of PS-exposing neurons in both unstimulated and LPS-challenged conditions (Fig 4E,F). To validate the impact of MFGE8, we pretreated primary microglia from Abcd1−/− mice with either MFGE8 (50 ng/ml) or MFGE8 antibody for 12 hours and then assessed phagocytosis. We found a significant increase in phagocytosis in MFGE8-treated microglia (Fig 4G,H; *p < 0.05), whereas exposure to MFGE8 antibody reduced phagocytic capacity (Fig 4I). These data suggest that genetic ablation of ABCD1 leads to increased secretion of MFGE8 by microglia and thereby contributes to phagocytosis of stressed neurons.

**LPC C26:0 Treatment Exposes PS on the Neuronal Cell Surface**

The most significant biochemical change caused by ABCD1 mutations is increased VLCFA levels including free fatty acid and LPC (in particular, C24:0 and C26:0) in plasma and tissues. To determine whether neurons exposed to high VLCFA levels have PS exposure on their surfaces, we treated neurons differentiated from ReN cells with both C26:0 free fatty acid (FFA C26:0) and LPC C26:0 and then determined PS exposure by Annexin V/FITC binding. FFA C26:0 treatment for 3 days at either 10 µM or 20 µM did not induce significant PS exposure on the cell surface (Fig 5A,C). However, there was a
remarkable dose-dependent PS exposure after LPC C26:0 treatment at both 10 μM and 20 μM. Further staining with cleaved caspase 3 did not reveal a notable positive signal with either FFA C26:0 or LPC C26:0 treatment (Fig 5B). In addition, the neuronal marker, TuJ1, did not show significant morphological changes (Fig 5B), suggesting that neurons were still alive after LPC C26:0 treatment despite PS exposure.

LPC C26:0 Enhances MFG8 Expression in Microglia

To examine whether VLCFA has any effect on MFG8 expression, we first treated microglial cell lines (N9) with 30 μM of FFA C26:0, LPC C16:0, and LPC C26:0 separately for 3 days. LPC C26:0 significantly increased MFG8 mRNA expression whereas FFA C26:0 and LPC C16:0 did not have an effect (Fig 6A). Finally, we also treated primary isolated microglia from both WT and Abcd1−/− mice with 15 μM of LPC C26:0 and found significant increase of MFG8 expression at both mRNA (Fig 6B; p < 0.05) and protein level (Fig 6C; p < 0.05).

In the Presence of ABCD1-Deficient Microglia LPC C26:0 Mediates Damage to Neurons

To assess whether Abcd1−/− microglia have a direct impact on neurite growth, we isolated microglia from
WT and Abcd1+/− mice and then cocultured them with differentiated neurons for 4 days. In this coculture, we found no change in neurite density and morphology, suggesting that Abcd1+− microglia alone have no direct impact on neurite growth in vitro (Fig 7A,B). However, when 15 μM of LPC C26:0 was supplied, it decreased Tuj1 expression by 20%, implying damage to the neuron in the coculture system (Fig 7C,D), and treatment with MFGE8 antibody (MFGE8 Ab) in the coculture system slightly alleviated the adverse impact (Fig 7D). Higher magnification images show microglia phagocytosing neurons in the LPC C26:0 supplemented coculture system (Fig 7E), with degenerated axons frequently observed (Fig 7F). Quantification data suggested increased axon degeneration after LPC C26:0 supplementation in the coculture system whereas MFGE8 antibody treatment exhibited a protective effect on axon degeneration (Fig 7G).

**Human AMN Spinal Cord Displays Microglia Activation and Increased Expression of Phagocytosis-Related Markers and Synaptic Dysfunction**

To determine whether our observation in AMN mice were applicable to humans, spinal cord tissue from a pure AMN case encompassing the corticospinal tract and dorsal columns was examined. Luxol fast blue (LFB) staining showed reduced myelin staining in the dorsal
In the spinal cord of AMN, mild myelin loss was observed, commensurate with axonal loss (Fig 8A). Dramatic increases in CD68 and IBA1 staining were noted in the AMN spinal cord compared to the control group (Fig 8B), suggesting activation of microglia in the spinal cord of AMN. As a next step, we analyzed spinal cord from another 13 postmortem adult ALD tissues (Fig 8). Initial analysis was performed separately for patients who, by history, were thought to have cerebral ALD alone versus cerebral ALD plus AMN (data not shown). Because the ALD spinal cord showed no significant differences between one another and all male patients in adulthood manifest some degree of AMN, data were grouped and displayed as adult ALD tissues (Fig 8).

Significant reduction in SYP gene expression indicated synaptic dysfunction in ALD spinal cord. In contrast to mice, some human ALD spinal cord showed perivascular macrophages (thick arrow in Fig 8B) with significant increases in Ccl2 and Ccr2 (Fig 8C), indicating infiltration of monocytes.

**Discussion**

The present study was designed to investigate the role of the innate immune system in the pathogenesis of AMN. Given that the more acute phenotype of cerebral ALD is associated with microglial activation in the presence of lymphocytic inflammation, we were surprised to find that microglial activation in AMN mouse and human spinal cord not only lacked proinflammatory markers, but was also accompanied by distinct upregulation of phagocytosis. In ABCD1-deficient mice, we showed that microglial activation precedes synapse loss, and that aberrant phagocytosis impairs neuronal projections.
Axonal degeneration in AMN causes selective length-dependent injury to both the corticospinal tract and dorsal columns. We find microglial activation to be the predominant pathology of the spinal cord in both humans and mice with AMN. In ABCD1-deficient mice, IBA1 expression is already significantly elevated at 2 months of age, a year before markers of axonal degeneration are detectable. We confirmed past reports that within human AMN spinal cord, inflammation is mild or absent. Furthermore, Abcd1−/− vessels in spinal cord were intact (data not shown), and human tissue showed no blood-borne lymphocytes, no inflammatory lesions, and only minimal clustering of macrophages around vessels (Fig 8).

If microglial activation is an early change yet no inflammation is observed in spinal cord, what mediates pathology? Un Expectedly, we found that even in young Abcd1−/− mice, several key receptors and signaling molecules for phagocytosis are elevated. Trem2 gene expression is markedly increased early on, and over time increased expression of milk fat globule EGF factor 8 (MFGE8; also known as lactadherin or SED1) and C1q are observed. MFGE8 is known to opsonize dying cells and bind to integrins on the surface of phagocytic cells, thus mediating engulfment. Importantly, the aberrant lipid accumulating in ALD, LPC C26:0, further aggravates ABCD1-deficient microglia, leading to even higher MFGE8 expression. Damage to the neuron ultimately arises from the combination of altered microglial function and the specific chemical environment. Our findings are in line with recent observations that microglial engulfment of live neurons plays a significant role in neurodegenerative diseases.

Both the literature and our own experiments confirm that phagocytosis of neurons and axons with...
exposed PS can be mediated by MFGE8. In general, two prerequisites are necessary for microglial engulfment of live neurons and axons. The first is activated microglia with upregulated microglial receptors and opsonins like MFGE8, which can recognize a stressed neuron and tag it for engulfment. The second is PS exposure on the neuronal cell surface, which can occur as a result of oxidative stress, an increase in calcium levels, or adenosine triphosphate depletion, among other possible mechanisms.29–31

PS exposure is not itself toxic to neurons, but rather marks the neuron for selective removal by microglia. If activated microglia are present, this results in phagocytosis of the PS-exposed neurons.26–28,32 In line with this thinking, our data suggest that LPC C26:0, in particular at low dose (15 μM), does not cause significant neuronal toxicity in culture despite leading to PS exposure.

In addition to upregulation of phagocytosis, we found evidence of aberrant complement activation in Abcd1−/− spinal cord, which may provide further mechanistic insights into the pathogenesis of neurodegeneration attributed to ABCD1 deficiency. Colocalization of C1q and synaptophysin in Abcd1−/− mice of different ages suggests that microglia mediate synaptic pruning. During postnatal development and in the normal aging process, the complement pathway plays a critical role in the refinement of neural circuits.10,33–36 In AMN, abnormal
synaptic pruning attributed to excessive microglial activation may instead promote neurodegeneration, as also observed in many neurodegenerative disease models.\(^\text{10,36}\)

By what mechanism are MFGE8 and C1q upregulated in Abcd1\(^{−/−}\) mouse spinal cord? In vitro CRISPR knockout of ABCD1 gene in N9 microglia did not show upregulation of C1q or MFGE8 (data not shown), suggesting an indirect non-cell-autonomous process. Khalifeh-Soltani et al reported MFGE8 upregulation by high-fat treatment and demonstrated a role of MFGE8 in absorption of dietary triglycerides and the cellular uptake of fatty acids.\(^\text{37}\)

In our study, increased VLCFA, in particular C26:0 LPC, triggered the expression of MFGE8, suggesting the altered metabolic milieu as one potential factor impacting MFGE8. In addition, we found increased TGFb1 and TGFb2 expression in Abcd1\(^{−/−}\) spinal cord (Fig 3). Given that VLCFAs have no significant impact upon TGFb1 expression in primary microglia (data not shown), the mechanism by which MFGE8 and C1q are increased in AMN spinal cord are likely multifactorial.

The TGF signaling pathway has long been considered to play a key role in the regulation of inflammation and microglia activation.\(^\text{38,39}\) It has also been shown to be a key regulator of C1q expression and synaptic pruning in the developing visual system.\(^\text{40}\) Besides, TGFb1 can also upregulate MFGE8 expression and increase microglia-mediated engulfment of apoptotic cells.\(^\text{20}\) Hence, the increased TGFb signaling could potentially stimulate both C1q and MFGE8. Many cell types in the central nervous system can produce TGFb1, including microglia, astrocytes, endothelial cells, and neurons. We previously found that ABCD1 silencing in human brain microvascular endothelial cells dramatically increased TGFb1 levels.\(^\text{41}\)

Our data suggest that low-dose VLCFAs (15 \(\mu\text{M}\)) incorporated into phospholipids may contribute to long-tract axon degeneration, but only in the presence of primed phagocytic microglia. Neither human nor mouse AMN spinal cord displays cell death despite accumulation of LPC C26:0.\(^\text{42}\) For some time, it has been known that excess VLCFA (40 \(\mu\text{M}\) and above) affects membrane function and causes toxicity to adrenocortical cells, oligodendrocytes, astrocytes, and neurons. For example, excess free VLCFA induces depolarization of mitochondria and deregulation of the intracellular calcium homeostasis, and in the brain, this can cause activation and apoptosis of microglia.\(^\text{43,44}\) However, more relevant than these supraphysiological doses are the lower doses that...
we used, which in isolation do not cause cell death. Our findings call into question whether free VLCFAs are truly toxic under physiological conditions in human disease; rather, the findings suggest that VLCFAs incorporated in LPC induce neuronal stress that leads to phagocytosis by primed, ABCD1-deficient microglia.

Previously, neuronal loss during brain inflammation had been assumed to be attributed to phagocytosis of neurons subsequent to their apoptotic or necrotic death. However, recently it was shown that, under inflammatory conditions in primary rat cultures of neurons and glia, phagocytosis itself actively induces neuronal death. Although the development of AMN occurs in the absence of overt inflammation, early oxidative damage including increased oxidative lesions and altered antioxidant defense is detected in the mouse spinal cord and human fibroblast cell lines. As the well-known inducer of phosphatidylserine exposure, oxidative stress in AMN spinal cord may also prime for phagocytosis. Furthermore, activated microglia themselves can also secrete nitric oxide that causes PS exposure and leads to phagocytosis. We observed increased iNOS expression in both primary cultured microglia and 3-month spinal cord tissue following LPS challenge in Abcd1−/− mice.

Several limitations to our study apply. Human spinal cord tissue sections are limited to rare cases of adult ALD and represent end-stage pathology. The contribution of other cell types, such as astrocytes, oligodendrocytes, and endothelial cells, was beyond the scope of our current investigation, and these cells may play a role in the cascade of neurodegeneration. Future work evaluating phagocytic receptors in transgenic and knockout animals is needed to corroborate our findings.

In sum, our data indicate a novel form of neurodegeneration, where lack of ABCD1 induces microglial activation and priming, aberrant lipids expose eat-me signals on otherwise viable neurons, and neurons degenerate through phagocytosis. Ultimately, blocking phagocytosis may prevent some forms of neurodegeneration and thus requires further exploration in AMN.

Acknowledgment

This work was supported by grants from the Leblang Charitable Foundation, the University of Pennsylvania Orphan Disease Center, the Applied Genetic Technologies Corporation, and NIH (R01 NINDS).

Author Contributions

Y.G. and F.E. were responsible for conception and design of the study. Y.G., N.S., F.L., M.F., R.T., D.Y.K., A.B., J.K., and F.E. were responsible for data acquisition and analysis. Y.G, NS, FL, FE were responsible for drafting the manuscript and figures. All authors have read, critically revised, and approved the manuscript before submission.

Potential Conflicts of Interest

Nothing to report.

References

1. Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993;361:726–730.
2. Mosser J, Lutz Y, Stocekel ME, et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 1994;3:265–271.
3. Berger J, Forss-Petter S, Eichler FS. Pathobiology of X-linked adrenoleukodystrophy. Biochimie 2014;98:135–142.
4. Eichler FS, Ren JQ, Cossoy M, et al. Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy? Ann Neurol 2008;63:729–742.
5. Ho JK, Moser H, Kishimoto Y, Hamilton JA. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J Clin Invest 1995;96:1455–1463.
6. Igarashi M, Schaumburg HH, Powers J, et al. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976;26:851–860.
7. Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999;45:100–110.
8. Hubbard WC, Moser AB, Liu AC, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009;97:212–220.
9. Fouquet F, Zhou JM, Ralston E, et al. Expression of the adrenoleukodystrophy protein in the human and mouse central nervous system. Neurobiol Dis 1997;3:271–285.
10. Hong S, Beja-Glasser VF, Nfonom Y, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016;352:712–716.
11. Ransohoff RM, El Khoury J. Microglia in health and disease. Cold Spring Harb Perspect Biol. 2015 Sep 9. doi: 10.1101/cshperspect.a020560. [Epub ahead of print]
12. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000;59:89–102.
13. Dumsner M, Bauer J, Lassmann H, Berger J, Forss-Petter S. Lack of adrenoleukodystrophy protein enhances oligodendrocyte disturbance and microglia activation in mice with combined Abcd1/Mag deficiency. Acta Neuropathol 2007;114:573–586.
14. Pujol A, Ferrer I, Camps C, et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 2004;13:2997–3006.
15. Tamashiro TT, Dalgaard CL, Byrnes KR. Primary microglia isolation from mixed glial cell cultures of neonatal rat brain tissue. J Vis Exp 2012;(66):e3814.
16. Kim YH, Choi SH, D’Avanzo C, et al. A 3D human neural cell culture system for modeling Alzheimer’s disease. Nat Protoc 2015;10:985–1006.
17. Pujol A, Hindelang C, Callizot N, et al. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse
model for adrenomyeloneuropathy. Hum Mol Genet 2002;11:499–505.

18. Nomura K, Vilalta A, Allendorf DH, Hornik TC, Brown GC. Activated microglia desialylate and phagocytose cells via neuraminidase, galectin-3, and mer tyrosine kinase. J Immunol 2017;198:4792–4801.

19. Ribes S, Ebert S, Czesnik D, et al. Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. Infect Immun 2009;77:557–564.

20. Spittau B, Rilka J, Steinath E, Zöller T, Kriegstein K. TGFβ1 increases microglia-mediated engulfment of apoptotic cells via upregulation of the milk fat globule-EGF factor 8. Glia 2015;63:142–153.

21. Schaumburg HH, Powers JM, Raine CS, et al. Adrenomyeloneuropathy: a probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic, and biochemical aspects. Neurology 1977;27:1114–1119.

22. Powers JM. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin Neuropathol 1985;4:181–199.

23. van Geel BM, Koelman JH, Barth PG, Ongerboer de Visser BW. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology 1996;46:112–118.

24. Brown GC, Neher JJ. Microglial phagocytosis of live neurons. Nat Rev Neurosci 2014;15:209–216.

25. Brown GC, Vilalta A. How microglia kill neurons. Brain Res 2015;1628(pt B):289–297.

26. Neher JJ, Emmrich JV, Fricker M, et al. Phagocytosis executes delayed neuronal death after focal brain ischemia. Proc Natl Acad Sci U S A 2013;110:E4098–E4107.

27. Fricker M, Neher JJ, Zhao JW, et al. MFG-E8 mediates primary phagocytosis of viable neurons during neuroinflammation. J Neurosci 2012;32:2657–2666.

28. Neenkiryte U, Brown GC. Lactadherin/MFG-E8 is essential for microglia-mediated neuronal loss and phagocytosis induced by amyloid beta. J Neurochem 2013;126:312–317.

29. Suzuki J, Fuji T, lmao T, et al. Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. J Biol Chem 2013;288:13035–13036.

30. Tyurina YY, Basova LV, Konduru NV, et al. Nitrosative stress inhibits the aminophospholipid translocase resulting in phosphatidylserine externalization and macrophage engulfment: implications for the resolution of inflammation. J Biol Chem 2007;282:8498–8509.

31. Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. Xx-related protein 8 and CED-8 promote phosphatidyserine exposure in apoptotic cells. Science 2013;341:403–406.

32. Neher JJ, Neniskyte U, Zhao JW, et al. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol 2011;186:4973–4983.

33. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058–1066.

34. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012;74:691–705.

35. Stephan AP, Madison DV, Mateos JM, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci 2013;33:13460–13474.

36. Lui H, Zhang J, Makinson SR, et al. Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation. Cell 2016;165:921–935.

37. Khalifeh-Soltani A, McKlery W, Sakuma S, et al. Mfge8 promotes obesity by mediating the uptake of dietary fats and serum fatty acids. Nat Med 2014;20:175–183.

38. Paglinawan R, Malipiero U, Schlapbach R, Frei K, Reth W, Fontana A. TGFbeta directs gene expression of activated microglia to an anti-inflammatory phenotype strongly focusing on chemokine genes and cell migratory genes. Glia 2003;44:219–231.

39. Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci 2014;17:131–143.

40. Bialas AR, Stevens B. TGF-beta signaling regulates neuronal C1q expression and developmental synaptic refinement. Nat Neurosci 2013;16:1773–1782.

41. Musolino PL, Gong Y, Snyder JM, et al. Brain endothelial dysfunction in cerebral adrenoleukodystrophy. Brain 2015;138(pt 11):3206–3220.

42. Gong Y, Mu D, Prabhakar S, et al. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Mol Ther 2015;23:824–834.

43. Hein S, Schonfeld P, Kahler S, Reiser G. Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet 2008;17:1750–1761.

44. Whitcomb RW, Linehan WM, Knezek RA. Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropic responsiveness of human adrenocortical cells in vitro. J Clin Invest 1998;91:185–188.

45. Kinsner A, Pilotto V, Deininger S, et al. Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation. J Neurochem 2005;95:1132–1143.

46. Fourcade S, López-Erasquin J, Galino J, et al. Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 2008;17:1762–1773.